<DOC>
	<DOCNO>NCT01040416</DOCNO>
	<brief_summary>The objective study identify incidence rate ; describe risk factor , clinical presentation , endoscopic treatment ; assess morbidity , mortality , overall performance management patient actively bleed marginal ulcer Roux-en-Y gastric bypass ( RYGB ) surgery .</brief_summary>
	<brief_title>Endoscopic Therapy Bleeding Marginal Ulcers After Gastric Bypass</brief_title>
	<detailed_description>Marginal ulceration `` MU '' , present ulcer margin gastrojejunostomy jejunal side , common late complication RYGB . Its incidence RYGB range low 0.6 high 16 % . In hand laparoscopic hand-sewn technique GJ , incidence 1.4 % . The presence specific technical factor - staple-line dehiscence gastro-gastric fistula , enlarge pouch , foreign material local ischemia - environmental factor - tobacco , NSAID´s , alcohol consumption , H pylori infection among others - associate marginal ulceration however exact etiopathogenesis completely elucidate . Similar peptic ulcer disease ( PUD ) , marginal ulcer respond medical therapy , specifically sucralfate acid-lowering medication . In contrast , complicate marginal ulcer - perforation , bleeding , chronicity ( obstruction , penetration , intractability ) - warrant operative intervention . Early presentation hemorrhage RYGB mostly relate staple-line failure may result either GI intraabdominal hemorrhage . When indicated , operative intervention consist either endoscopic therapy , re-operation , . In contrast , late presentation gastrointestinal hemorrhage RYGB mostly secondary bleed marginal ulcer however complicate peptic ulcer disease present exclude stomach duodenum well . Most literature available management GI hemorrhage RYGB early presentation hemorrhage secondary staple-line failure . Hence , option endoscopic hemostatic therapy describe scenario I ) injection therapy , II ) coagulation therapy , III ) endoscopic clipping , IV ) combine modality ( example injection &amp; coagulation injection clip ) . The feasibility , reliability , reproducibility , efficacy , validity safety endoscopic hemostatic therapy acutely bleed peptic ulcer well document . Multiple risk-stratification tool upper-GI hemorrhage also develop Blatchford , clinical complete Rockall score , Forrest classification . Moreover , pre post endoscopic scheme PPI´s therapy patient bleed peptic ulcer effective cost-saving . However , All validate obese population status post RYGB complicate bleed marginal ulcer . Summarizing , scant information management late complication gastric bypass especially widespread adoption laparoscopic approach modern anatomical construct Roux-en-Y Gastric Bypass surgery . We formally analyze management efficacy patient actively bleed marginal ulcer Roux-en-Y gastric bypass ( RYGB ) surgery .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<criteria>patient status post laparoscopic RYGB surgery active gastrointestinal hemorrhage secondary marginal ulcer bleed marginal ulcer bariatric procedure stapleline bleed RYGB irondeficiency anemia ( chronic ) secondary nonactively bleed marginal ulcer RYGB source GI bleed different marginal ulcer staplelines , complicate PUD , surgical medical cause GI hemorrhage miss record and/or unreachable patient scant information analysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>complicate marginal ulcer</keyword>
	<keyword>complex marginal ulcer</keyword>
	<keyword>complication gastric bypass</keyword>
	<keyword>gastrointestinal hemorrhage</keyword>
</DOC>